menu
    • menu

    Company profile for Kezar Life Sciences

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2015 and based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. We are translating our innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in three Phase 2 trials across five se...
    Founded in 2015 and based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. We are translating our innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in three Phase 2 trials across five separate autoimmune diseases of high unmet need - lupus nephritis, dermatomyositis/polymyositis, and autoimmune hemolytic anemia/immune thrombocytopenia.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kezar Life SciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4000 Shoreline Court, Suite 300, South San Francisco, CA 94080
    Telephone
    Telephone
    (650) 822-5600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kezarlifesciences.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tang Returns As Aurinia CEO With $50M Offer After Kezar Buyout
    Tang Returns As Aurinia CEO With $50M Offer After Kezar Buyout

    30 Mar 2026

    // BIOSPACE

    https://www.biospace.com/business/after-missing-kezar-buyout-in-2024-tang-returns-as-ceo-of-aurinia-with-50m-offer

    BIOSPACE
    30 Mar 2026
    Share Share
    French Biotech Pens $128M Deal For Kezar Protein Degrader Work
    French Biotech Pens $128M Deal For Kezar Protein Degrader Work

    12 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fledgling-french-biotech-pens-128m-deal-kezars-preclinical-protein-degrader-program

    FIERCE BIOTECH
    12 Mar 2026
    Share Share
    Enodia Therapeutics Strengthens Sec61 Portfolio Through
    Enodia Therapeutics Strengthens Sec61 Portfolio Through

    12 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260312627573/en/Enodia-Therapeutics-Strengthens-Sec61-Portfolio-Through-Acquisition-of-Preclinical-Assets-from-Kezar-Life-Sciences

    BUSSINESSWIRE
    12 Mar 2026
    Share Share
    Kezar Updates on Zetomipzomib for Autoimmune Hepatitis
    Kezar Updates on Zetomipzomib for Autoimmune Hepatitis

    09 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-09/kezar-life-sciences-announces-regulatory-update-on-zetomipzomib-program-in-autoimmune-hepatitis

    PHARMIWEB
    09 Jan 2026
    Share Share
    Kezar Life Sciences Reports Third Quarter 2025 Financial Results
    Kezar Life Sciences Reports Third Quarter 2025 Financial Results

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112668726/en/Kezar-Life-Sciences-Reports-Third-Quarter-2025-Financial-Results

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    Kezar Cuts 70% of Staff After FDA Cancels Autoimmune Meeting
    Kezar Cuts 70% of Staff After FDA Cancels Autoimmune Meeting

    10 Nov 2025

    // BIOSPACE

    https://www.biospace.com/business/kezar-loses-70-of-staff-after-fda-cancels-meeting-on-autoimmune-asset

    BIOSPACE
    10 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search